A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer

被引:13
|
作者
Clement-Duchene, Christelle [1 ,2 ]
Natale, Ronald B. [3 ]
Jahan, Thierry [4 ]
Krupitskaya, Yelena [1 ]
Osarogiagbon, Raymond [5 ]
Sanborn, Rachel E. [6 ]
Bernstein, Eric D. [6 ]
Dudek, Arkadiusz Z. [7 ]
Latz, Jane E. [8 ]
Shi, Peipei [8 ]
Wakelee, Heather A. [1 ]
机构
[1] Stanford Univ, Stanford Canc Inst, Stanford, CA 94305 USA
[2] CHU Nancy, Chest Dept, Nancy, France
[3] Cedars Sinai Canc Ctr, Los Angeles, CA USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
[5] Univ Tennessee, Memphis, TN USA
[6] Providence Portland Med Ctr, Portland, OR USA
[7] Univ Minnesota, Minneapolis, MN USA
[8] Eli Lilly & Co, Indianapolis, IN 46285 USA
关键词
NSCLC; Erlotinib; Enzastaurin; PROTEIN-KINASE-C; BETA INHIBITOR; PKC-BETA; SELECTIVE INHIBITOR; ENDOTHELIAL-CELLS; SIGNALING PATHWAY; DOSE-ESCALATION; SOLID TUMORS; TRIAL; CHEMOTHERAPY;
D O I
10.1016/j.lungcan.2012.06.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Regardless of epidermal growth factor receptor (EGFR) mutation status, erlotinib improves survival for patients with advanced non-small cell lung cancer (NSCLC) after one or more chemotherapy regimens. Enzastaurin is an oral serine/threonine kinase inhibitor. This phase II study was designed to evaluate the efficacy and safety of erlotinib and enzastaurin in NSCLC, a combination with promise to overcome EGFR resistance based on preclinical models. Methods: Eligible patients with advanced NSCLC (IIIB or IV) who had failed one or two prior systemic treatment regimen(s) were enrolled and received erlotinib 150 mg/day and enzastaurin 500 mg/day (after a 1125-mg loading dose on day 1, cycle 1), both orally in 28-day cycles. The primary endpoint was progression-free survival (PFS). Results: From January 2008 to July 2009,49 patients were enrolled: 29(59%) men and 20(41%) women; 8 (16%) were non-smokers. The median PFS was 1.7 months (one-sided 90% Cl: 1.5-NA) and median overall survival (OS) was 8.3 months (95% CI: 5.3-14.3). Five patients had partial response, for an overall response rate of 10.2%; the disease control rate was 30.6% (responders + 10 patients with stable disease). Grade 3-4 drug-related adverse events in >= 5% of patients were diarrhea, acne, and nausea. One possibly drug-related death due to interstitial lung disease occurred during the study. Conclusions: In previously treated, unselected, advanced NSCLC patients, the addition of enzastaurin to erlotinib did not improve PFS, response, or OS compared with historical data of single-agent erlotinib, but was well tolerated. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:57 / 62
页数:6
相关论文
共 50 条
  • [1] Phase I and Pharmacokinetic Study of Erlotinib Administered in Combination With Amrubicin in Patients With Previously Treated, Advanced Non-small Cell Lung Cancer
    Otani, Sakiko
    Hamada, Akinobu
    Sasaki, Jiichiro
    Wada, Mayuko
    Yamamoto, Michiko
    Ryuge, Shinichiro
    Takakura, Akira
    Fukui, Tomoya
    Yokoba, Masanori
    Mitsufuji, Hisashi
    Toyooka, Issei
    Maki, Sachiyo
    Kimura, Michiko
    Hayashi, Nobuatsu
    Ishihara, Mikiko
    Kasajima, Masashi
    Hiyoshi, Yasuhiro
    Katono, Ken
    Asakuma, Maiko
    Igawa, Satoshi
    Kubota, Masaru
    Katagiri, Masato
    Saito, Hideyuki
    Masuda, Noriyuki
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (04): : 405 - 410
  • [2] A Randomized Phase 2 Study of Erlotinib Alone and in Combination with Bortezomib in Previously Treated Advanced Non-small Cell Lung Cancer
    Lynch, Thomas J.
    Fenton, David
    Hirsh, Vera
    Bodkin, David
    Middleman, Edward L.
    Chiappori, Alberto
    Halmos, Balazs
    Favis, Reyna
    Liu, Hua
    Trepicchio, William L.
    Eton, Omar
    Shepherd, Frances A.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (08) : 1002 - 1009
  • [3] Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer
    Besse, B.
    Leighl, N.
    Bennouna, J.
    Papadimitrakopoulou, V. A.
    Blais, N.
    Traynor, A. M.
    Soria, J. -C.
    Gogov, S.
    Miller, N.
    Jehl, V.
    Johnson, B. E.
    ANNALS OF ONCOLOGY, 2014, 25 (02) : 409 - 415
  • [4] Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
    Kelley, Michael J.
    Jha, Gautam
    Shoemaker, Debra
    Herndon, James E., II
    Gu, Lin
    Barry, William T.
    Crawford, Jeffrey
    Ready, Neal
    CANCER INVESTIGATION, 2017, 35 (01) : 32 - 35
  • [5] Efficacy and Safety of Erlotinib in Previously Treated Advanced Non-Small Cell Lung Cancer
    Karaca, Halit
    Geredeli, Caglayan
    Kaplan, M. Ali
    Demirci, Umut
    Alici, Suleyman
    Artac, Mehmet
    Isikdogan, Abdurrahman
    Benekli, Mustafa
    Balakan, Ozan
    Arpaci, Erkan
    Budakoglu, Burcin
    Uncu, Dogan
    Guler, Tunc
    Berk, Veil
    Ozkan, Metin
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2013, 23 (01): : 1 - 6
  • [6] PHASE II TRIAL OF ERLOTINIB IN PREVIOUSLY TREATED PATIENTS WITH NON-SMALL CELL LUNG CANCER
    Okano, Yoshio
    Shinohara, Tsutomu
    Machida, Hisanori
    Hatakeyama, Nobuo
    Takeuchi, Eiji
    Doi, Hiroyuki
    Kubota, Tetsuya
    Yokoyama, Akihito
    Ogushi, Fumitaka
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1175 - S1176
  • [7] PHASE I AND PHARMACOKINETIC STUDY OF ERLOTINIB ADMINISTERED IN COMBINATION WITH AMRUBICIN IN PATIENTS WITH PREVIOUSLY TREATED, ADVANCED NON-SMALL CELL LUNG CANCER
    Otani, Sakiko
    Hamada, Akinobu
    Sasaki, Jiichiro
    Yamamoto, Michiko
    Ryuge, Shinichiro
    Takakura, Akira
    Fukui, Tomoya
    Yokoba, Masanori
    Mitsufuji, Hisashi
    Toyooka, Issei
    Maki, Sachiyo
    Kubota, Masaru
    Katagiri, Masato
    Saito, Hideyuki
    Masuda, Noriyuki
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1165 - S1165
  • [8] Phase I/II study of gefitinib (IressaA®) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer
    Han, Ji-Youn
    Lee, Soo Hyun
    Lee, Geon Kook
    Yun, Tak
    Lee, Young Joo
    Hwang, Kum Hui
    Kim, Jin Young
    Kim, Heung Tae
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (03) : 475 - 483
  • [9] Phase II Study of Erlotinib in Japanese Patients with Advanced Non-small Cell Lung Cancer
    Takahashi, Toshiaki
    Yamamoto, Nobuyuki
    Nukiwa, Toshihiro
    Mori, Kiyoshi
    Tsuboi, Masahiro
    Horai, Takeshi
    Masuda, Noriyuki
    Eguchi, Kenji
    Mitsudomi, Tetsuya
    Yokota, Soichiro
    Segawa, Yoshihiko
    Ichinose, Yukito
    Fukuoka, Masahiro
    Saijo, Nagahiro
    ANTICANCER RESEARCH, 2010, 30 (02) : 557 - 563
  • [10] Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer
    Kim, Young Saing
    Cho, Eun Kyung
    Woo, Hyun Sun
    Hong, Junshik
    Ahn, Hee Kyung
    Park, Inkeun
    Sym, Sun Jin
    Kyung, Sun Young
    Kang, Shin Myung
    Park, Jeong-Woong
    Jeong, Sung Hwan
    Park, Jinny
    Lee, Jae Hoon
    Shin, Dong Bok
    CANCER RESEARCH AND TREATMENT, 2016, 48 (01): : 80 - 87